Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Opaganib in mCRPC progressing on abiraterone or enzalutamide
NCT04207255Phase 2Completed
- Sponsor
- Medical University of South Carolina
- Start
- Mar 2020
- Primary completion
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of Opaganib in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Medical University of South Carolina. Started Mar 2020; status: completed.
02
Drugs
Opaganib
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT04207255.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04207255.